These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8125037)

  • 21. Azithromycin versus doxycycline for treatment of erythema migrans: clinical and microbiological findings.
    Strle F; Preac-Mursic V; Cimperman J; Ruzic E; Maraspin V; Jereb M
    Infection; 1993; 21(2):83-8. PubMed ID: 8387966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single-dose doxycycline for the prevention of Lyme disease.
    Leenders AC
    N Engl J Med; 2001 Nov; 345(18):1349; author reply 1349-50. PubMed ID: 11794161
    [No Abstract]   [Full Text] [Related]  

  • 23. [Skin manifestations of infection by Borrelia burgdorferi].
    Soria C; Freire P; Serrano MJ; Guerrero A
    Enferm Infecc Microbiol Clin; 1990 Jan; 8(1):36-42. PubMed ID: 2095903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study on clinical picture of erythema migrans.
    Flisiak I; Chodynicka B; Laudańska H; Reduta T; Stefańska-Sulik E; Puciło K; Lukaszuk C
    Rocz Akad Med Bialymst; 1996; 41(1):78-82. PubMed ID: 8673809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Solitary erythema migrans: a clinical, laboratory and epidemiological study of 77 Dutch patients.
    Kuiper H; Cairo I; Van Dam A; De Jongh B; Ramselaar T; Spanjaard L; Dankert J
    Br J Dermatol; 1994 Apr; 130(4):466-72. PubMed ID: 8186111
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical characteristics of Lyme disease in 12 cases].
    Anlar FY; Durlu Y; Aktan G; Açikgöz E; Bingöl N; Madencioğlu V; Anlar B
    Mikrobiyol Bul; 2003 Oct; 37(4):255-9. PubMed ID: 14748262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erythema migrans.
    Dandache P; Nadelman RB
    Infect Dis Clin North Am; 2008 Jun; 22(2):235-60, vi. PubMed ID: 18452799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody responses to borrelia IR(6) peptide variants and the C6 peptide in Swedish patients with erythema migrans.
    Tjernberg I; Sillanpää H; Seppälä I; Eliasson I; Forsberg P; Lahdenne P
    Int J Med Microbiol; 2009 Aug; 299(6):439-46. PubMed ID: 19138558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of erythema migrans in spite of treatment with antibiotics after a tick bite.
    Maraspin V; Lotric-Furlan S; Strle F
    Wien Klin Wochenschr; 2002 Jul; 114(13-14):616-9. PubMed ID: 12422612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cutaneous manifestations of Lyme borreliosis.
    Berger BW
    Rheum Dis Clin North Am; 1989 Nov; 15(4):627-34. PubMed ID: 2685922
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Comparison of test with antigen VlsE (C6) with tests with recombinant antigens in patients with Lyme borreliosis].
    Zajkowska JM; Kondrusik M; Pancewicz SA; Grygorczuk S; Jamiołkowski J; Stalewska J
    Pol Merkur Lekarski; 2007 Aug; 23(134):95-9. PubMed ID: 18044336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Therapy indications in positive Borrelia titer].
    Graninger W
    Internist (Berl); 1999 Feb; 40(2):216. PubMed ID: 10097982
    [No Abstract]   [Full Text] [Related]  

  • 33. [Borrelia infections of the skin--progress of knowledge since the discovery of Lyme disease].
    Garbe C
    Hautarzt; 1991 Jun; 42(6):356-65. PubMed ID: 1917458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of different Borrelia burgdorferi sensu lato strains for detection of immune response in patients with erythema migrans.
    Merljak Skocir L; Ruzić-Sabljić E; Maraspin-Carman V; Lotric-Furlan S; Logar M; Strle F
    Int J Med Microbiol; 2008 Jul; 298(5-6):493-504. PubMed ID: 17892971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Erythema migrans with multiple lesions].
    Constantin C; Peter O; Cerottini J; Derighetti M; Panizzon R; Guggisberg D
    Ann Dermatol Venereol; 2000 May; 127(5):513-6. PubMed ID: 10863185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunoblot analysis of the seroreactivity to recombinant Borrelia burgdorferi sensu lato antigens, including VlsE, in the long-term course of treated patients with erythema migrans.
    Glatz M; Fingerle V; Wilske B; Ambros-Rudolph C; Kerl H; Müllegger RR
    Dermatology; 2008; 216(2):93-103. PubMed ID: 18216470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of exposure to tick-bites on the course of lyme borreliosis in Bialowieza residents].
    Załezny W; Flisiak R; Prokopowicz D
    Przegl Epidemiol; 2002; 56(3):419-24. PubMed ID: 12608091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment of Borrelia burgdorferi infection].
    Oteo JA; Martínez de Artola V
    Enferm Infecc Microbiol Clin; 1991 Jan; 9(1):52-4. PubMed ID: 2029560
    [No Abstract]   [Full Text] [Related]  

  • 39. [Morphea--a tick transmitted borreliosis of the skin? A contribution to the pathogenesis of circumscript scleroderma].
    Büchner SA
    Z Hautkr; 1989 Aug; 64(8):661-4, 667-9. PubMed ID: 2678791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Diagnostic possibilities and limitations in Lyme borreliosis].
    Satz N; Knoblauch M
    Schweiz Med Wochenschr; 1989 Dec; 119(52):1883-93. PubMed ID: 2692151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.